HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT
The present invention relates to an isoxazolidin-2-yl-substituted heteroaryl derivative and a pharmaceutical composition for cancer prevention or treatment, comprising the compound as an active ingredient. The compound exhibits high inhibitory activity against the wild type or mutants of at least one of ErbB2 and ErbB4 and thus can be useful for treating cancers in which ErbB2 and ErbB4 are expressed..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 10. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEE YOUNHO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-11-10, Last update posted on www.tib.eu: 2024-04-24, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
WO2022234965 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002718774 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002718774 | ||
| 003 | DE-627 | ||
| 005 | 20240426160255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002718774 | ||
| 035 | |a (EPA)WO2022234965 | ||
| 035 | |a (EPA)83932236 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEE YOUNHO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-11-10, Last update posted on www.tib.eu: 2024-04-24, Last updated: 2024-04-26 | ||
| 520 | |a The present invention relates to an isoxazolidin-2-yl-substituted heteroaryl derivative and a pharmaceutical composition for cancer prevention or treatment, comprising the compound as an active ingredient. The compound exhibits high inhibitory activity against the wild type or mutants of at least one of ErbB2 and ErbB4 and thus can be useful for treating cancers in which ErbB2 and ErbB4 are expressed. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HWANG SEONAH |e verfasserin |4 aut | |
| 700 | 0 | |a DO WOOMI |e verfasserin |4 aut | |
| 700 | 0 | |a SHIM INSEOB |e verfasserin |4 aut | |
| 700 | 0 | |a LEE HWA |e verfasserin |4 aut | |
| 700 | 0 | |a SON JUNGBEOM |e verfasserin |4 aut | |
| 700 | 0 | |a KIM NAMDOO |e verfasserin |4 aut | |
| 700 | 0 | |a KIM SUNGHWAN |e verfasserin |4 aut | |
| 700 | 0 | |a JUNG HONGRYUL |e verfasserin |4 aut | |
| 700 | 0 | |a YOO JIHYE |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 10. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:10 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83932236/publication/WO2022234965A1?q=WO2022234965 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 10 |c 11 | ||